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Hypercholesterolaemia is considered to be a principle risk factor for cardiovascular disease, having direct negative effects on the
myocardium itself, in addition to the development of atherosclerosis. Since hypercholesterolaemia affects the global cardiac gene
expression profile, among many other factors, it results in increased myocardial oxidative stress, mitochondrial dysfunction and
inflammation triggered apoptosis, all of which may account for myocardial dysfunction and increased susceptibility of the
myocardium to infarction. In addition, numerous experimental and clinical studies have revealed that hyperlcholesterolaemia
may interfere with the cardioprotective potential of conditioning mechanisms. Although not fully elucidated, the underlying
mechanisms for the lost cardioprotection in hypercholesterolaemic animals have been reported to involve dysregulation of the
endothelial NOS-cGMP, reperfusion injury salvage kinase, peroxynitrite-MMP2 signalling pathways, modulation of ATP-sensitive
potassium channels and apoptotic pathways. In this review article, we summarize the current knowledge on the effect of hy-
percholesterolaemia on the non-ischaemic and ischaemic heart as well as on the cardioprotection induced by drugs or ischaemic
preconditioning, postconditioning and remote conditioning. Future perspectives concerning the mechanisms and the design of
preclinical and clinical trials are highlighted.
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Introduction
Although cholesterol is one of the main constituents of cellu-
lar membranes and plays an important role in hormone and
bile acid synthesis, increased circulating levels, especially if
oxidized, are detrimental resulting in atherosclerosis and
thus in the development and progression of coronary, carotid
and peripheral vessels’ disease (Félix-Redondo et al., 2013).
Several years ago, clinical studies clearly showed a linear rela-
tion between the regression of cholesterol levels and the con-
sequent improvement of clinical outcome in patients
suffering from hypercholesterolaemia (Castelli et al., 1989;
Rubin et al., 1990). Hypercholesterolaemia is widely accepted
as a principal risk factor for coronary artery disease (CAD)
(Tiwari and Khokhar 2014), and patients with extremely in-
creased levels of cholesterol have an elevated risk of ischae-
mic events regardless of their genotype (Sniderman, et al.,
2014). Moreover, analysis of the Kaiser Permanente Heart
Study and Framingham Heart Study cohorts showed signifi-
cant associations between cholesterol levels and the risk for
cardiovascular mortality in individuals with and without a
history of CAD (Castelli et al., 1989; Rubin et al., 1990; Wong
et al., 1991).
Although, the observations from clinical trials and exper-
imental studies suggest an effect of cholesterol on myocardial
function (Huang et al., 2004), little is known about its effects
on cardiac function apart from CAD. Hypercholesterolaemia
has been proposed to have direct negative effects on the
myocardium itself, in addition to the development of athero-
sclerosis, with several studies demonstrating increased myo-
cardial injury in hypercholesterolaemic animals (Hoshida
et al., 1996a; Ferdinandy et al., 1998a; Scalia et al., 2001; see
for review by Ferdinandy, 2003; Osipov et al., 2009). Hyper-
cholesterolaemia alone increased myocardial necrosis by
45% over what was observed in normal fed animals (Osipov
et al., 2009), and impaired diastolic function in vitro as well
as in vivo (Onody et al., 2003; Huang et al., 2004; Varga et al.,
2013). Intracellular lipid accumulation in cardiomyocytes
and several alterations in the structural and functional prop-
erties of the myocardium have been observed in response to a
high cholesterol diet in rodents (Onody et al., 2003; Puskas
et al., 2004). Thus, it seems that hypercholesterolaemia is
not only detrimental for the vasculature but is also a risk
factor for increased cariomyocyte death and poor left ventric-
ular (LV) systolic function in patients following acute
myocardial infarction (AMI) (Corti et al., 2001). However,
the molecular mechanisms by which chronically elevated
cholesterol can detrimentally affect the cardiomyocyte are
poorly understood.
In this review article, we summarize the current
knowledge on the effect of hypercholesterolaemia on the
non-ischaemic and ischaemic heart, as well as on
cardioprotection induced by ischaemic preconditioning
(PC), postconditioning (PostC) and remote conditioning.
Additionally, we summarize the effects of hypercholesterol-
aemia on drug-induced cardioprotection as well as the effect
of antihyperlipidaemic drugs on cardioprotection. Future
perspectives concerning the mechanisms and the design of
preclinical and clinical trials are highlighted.
Effect of hypercholesterolaemia on the
myocardium
Hypercholesterolaemia causes endothelial
dysfunction
Numerous animal and clinical models have reported im-
paired endothelium-dependent and independent relaxation
in the presence of hypercholesterolaemia (Kawashima and
Yokoyama, 2004). Both acute and chronic elevations in blood
cholesterol induce nitro-oxidative stress in microvascular en-
dothelium that results from an increased generation of ROS
and a decreased bioavailability of NO (Davidson, 2010), up-
Tables of Links
TARGETS
Other protein targetsa Enzymesf
Bax Akt
Bcl-2 ERK1
GPCRsb ERK2
AT1 receptor GSK3β
Voltage-gated ion channelsc MMP2
KATP (Kir6.x) channels NOS
Other ion channelsd PCSK9
Connexin 43 (Cx43) PI3K
Nuclear hormone receptorse PKG
PPARα
LIGANDS
ADMA NO
cGMP Sevoflurane
Cyclosporine A (CsA) VCAM-1
Fasudil
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise
Guide to PHARMACOLOGY 2015/16 (a,b,c,d,e,fAlexander et al., 2015a,b,c,d,e,f).
BJP I Andreadou et al.
1556 British Journal of Pharmacology (2017) 174 1555–1569
regulated inflammation (Liu et al., 2009), inhibition of NOS
(Prasan et al., 2007), and increased cardiomyocyte apoptosis
(Wang et al., 2002).
ROS can be produced by a variety of cells that
have been implicated in the inflammatory responses to
hypercholesterolaemia, such as neutrophils, monocytes,
B-lymphocytes, platelets, mast cells, endothelial cells and
vascular smooth muscle cells (Stokes et al., 2002). Potential
sources of ROS in endothelial cells that have been identified
so far, include NADPH oxidase (Konior et al., 2014), xanthine
oxidase, enzymes involved in the metabolism of arachidonic
acid (lipoxygenase and cyclooxygenase) and NO synthases
(NOS) (reviewed in Stokes et al., 2002). One of the most im-
portant oxygen free radicals that is produced during hyper-
cholesterolaemia is superoxide anion (Landmesser et al.,
2000; Napoli and Lerman, 2001). The premise that this en-
hanced superoxide anion production is due to the elevated
blood cholesterol level is further supported by the observa-
tion that dietary correction of the hypercholesterolaemia re-
stores superoxide production to normal levels in isolated
arterial vessels (Ohara et al., 1995).
Both the expression and activity of NADPH oxidase is re-
sponsible, at least in part, for the increased superoxide anion
production in cholesterol-fed apolipoprotein B100 trans-
genic mice (Csont et al., 2007), and in postcapillary venules
in skeletal muscle of hypercholesterolaemic wildtype or
p47phox/ mice (Stokes et al., 2001). The enhanced super-
oxide anion production in arterial vessels from hypercholes-
terolaemic rabbits was blunted by treatment with either
allopurinol (a xanthine oxidase inhibitor) or heparin, which
competes with xanthine oxidase for binding to sulfated gly-
cosaminoglycans on endothelial cells (Landmesser et al.,
2000; Napoli and Lerman, 2001). Supporting the role of xan-
thine oxidase in ROS formation in hypercholesterolaemia,
superoxide generation by endothelial NOS (eNOS) occurs as
a result of uncoupling of L-argininemetabolism fromNO pro-
duction and a reduction in the eNOS cofactor
tetrahydrobiopterin (BH4) (Cosentino and Katusic, 1995;
Vergnani et al., 2000). Furthermore, an increased formation
of peroxynitrite, a toxic reaction product of superoxide and
NO, has been observed in hyperlcholesterolaemic rat myocar-
dium, and it is accompanied by a decrease in the bioavailabil-
ity of NO (Onody et al., 2003). Peroxynitrite induces DNA
damage, increases lipid peroxidation, and causes post-
translational modification of proteins (e.g. nitration and oxi-
dation of thiol groups) (Pacher et al., 2005), contributing to
the development of cardiac dysfunction observed in
hyperlcholesterolaemic rats.
The above observations in experimental studies have
been confirmed in humans; an increased NADPH oxidase-
mediated superoxide anion generation was observed in ves-
sels of hypercholesterolaemic patients (Assmann et al.,
1996; Guzik et al., 2000; Stokes et al., 2001; Itoh et al., 2002).
One additional potential mechanism by which
hypercholesterolaemia-derived oxidative stress could induce
cardiacmyocyte dysfunction and death is through disruption
of mitochondrial function. Increased oxidative stress during
hypercholesterolaemia enhances the mitochondrial perme-
ability transition (MPT) response. MPT dissipates the proton
electrochemical gradient (ΔΨm), leading to ATP depletion, fur-
ther ROS production, swelling and rupture of the
mitochondria, thereby releasing pro-apoptotic and pro-death
proteins into the cytosol (Halestrap, 2009). Hypercholesterol-
aemia increases mitochondrial oxidative stress and enhances
the MPT response in the porcine myocardium (McCommis
et al., 2011).
In conclusion, when blood cholesterol concentrations are
elevated, a low-grade systemic inflammatory response is elic-
ited inmultiple vascular beds andmay create an environment
in the extracellular compartment, possibly through the
generation of cytokines, oxidized molecules, for example, ox-
idized LDL, and other inflammatory mediators, that predis-
poses the endothelial cells of large arteries to an
inflammatory phenotype. Inflammation is associated with
increased ROS production that may overcome cellular de-
fence mechanisms leading to atherogenesis, protein damage
and enzyme inactivation, and eventually to loss of contrac-
tile function and vascular dysfunction (Misra et al., 2009),
which may also account for the increased susceptibility of
the myocardium to ischaemia–reperfusion injury and
infarction.
Hypercholesterolaemia affects cardiac gene
expression profile
Hypercholesterolaemia has been shown to affect the global
cardiac gene expression profile at the mRNA level in several
studies. In an early study, Puskas et al. reported that in the
hearts of rats on a cholesterol-enriched diet the expression
of numerous genes were modulated, including those in-
volved in energy metabolism, heat shock proteins, ion chan-
nels and structural proteins (Puskas et al., 2004). Similar
results were found in Zucker Diabetic Fatty (ZDF) animals
that also show a hypercholesterolaemic profile (Sárközy
et al., 2013). Hypercholesterolaemia has also been shown to
affect cardiac microRNA profile leading to increased NOX-4
expression and nitro-oxidative stress (Varga et al., 2013).
These results indicate that hypercholesterolaemia dramati-
cally changes cardiac transcriptomics affecting several known
and yet unknown cellular signalling pathways that may
impact cardiac function per se and the susceptibility of the
heart to ischaemia/reperfusion injury (see for a recent
review: Varga et al. 2015). Systematic analysis of the above
mentioned large scale transcriptomic data and more ‘omics’
data generated in future studies will be necessary to explore
alterations in the cellular signalling network of the hypercho-
lesterolaemic heart in comparison with those of the normal
heart (Varga et al. 2015; Perrino et al., 2017).
Effect of hypercholesterolaemia on
myocardial ischaemia/reperfusion
injury and cardioportection
Effect of hypercholesterolaemia on myocardial
ischaemia/reperfusion injury
Larger myocardial infarct sizes have an ominous long-term
prognosis compared to the smaller ones with increased mor-
bidity and mortality. Restriction of the final infarct size is
therefore mandatory for the health status and the future of
the patients suffering from AMI. How the presence of hyper-
cholesterolaemia affects infarct size is not clear, as the
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results that exist in the literature in different species and
models of hypercholesterolaemia are contradictory. In this
regard, larger infarctions have been described within the
first hours after acute ischaemia and reperfusion in
cholesterol-fed pigs (Osipov et al., 2009) and rabbits (Golino
et al., 1987). In rat isolated hearts exposed to hypercholes-
terolaemia, induced by a cholesterol enriched diet, the final
infarct size and the release of myocardial biomarkers of ne-
crosis and apoptosis were significantly increased, while the
recovery of LV function was not affected (Wu et al.,
2015b). In contrast, the infarct size was similar in hypercho-
lesterolaemic and normocholesterolaemic rats, but the LV re-
modelling and risk of developing heart failure were worse in
the animals fed the hypercholesterolaemic diet (Maczewski
and Maczewska, 2006). New Zealand White rabbits, fed for 4-
weeks with a hypercholesterolaemic diet and subjected to
30 min myocardial ischaemia and 2 h reperfusion, exhibited
a significantly increased infarct size compared with animals
fed a normal diet (Hoshida et al., 1996b; Jung et al., 2004). Ad-
ditionally, greater cardiac damage, as compared with normal-
fed rabbits, was also observed in cholesterol-fed rabbits that
were subjected to 60 min of myocardial ischaemia followed
by 60 min of reperfusion (Ma et al., 1996).
In contrast, using a model of 30 min ischaemia and 3 h re-
perfusion a similar degree of myocardial infarction was ob-
served in cholesterol-fed and normal fed rabbits (Andreadou
et al., 2006; 2012; 2016; Iliodromitis et al., 2006; 2010). Many
other studies have also shown similar infarct sizes in normal
and cholesterol-fed rats with no presence of significant ath-
erosclerosis (Giricz et al., 2009; Görbe et al., 2011; Csont
et al., 2013; Csonka et al., 2014). These divergent results are
possibly related to different species, diet and experimental
protocols. However, it can be concluded that the majority of
the studies show that hypercholesterolaemia increases infarct
size to some extent in animal models.
The mechanism of the effect of hypercholesterolaemia
on myocardial ischaemia–reperfusion injury is still not well
understood. It has been demonstrated that decreased
cardiac NO content, increased oxidative/nitrosative stress,
enhanced apoptotic cell death and dramatic changes in
the cardiac gene expression profile, as a consequence of hy-
percholesterolaemia (see for earlier review: Ferdinandy,
2003; Ferdinandy et al., 2007), may play an essential role
in the manipulation of myocardial ischaemia/reperfusion
injury in the presence of hypercholesterolaemia. Hypercho-
lesterolaemia decreases the bioavailability of NO with a
down-regulation of eNOS, in association with increased
production of oxygen-derived free radicals that may inacti-
vate NO. More specifically, increased plasma LDL inhibits
the active transport of L-arginine by endothelial cells,
uncoupling the eNOS pathway, hence limiting NO synthe-
sis and leading to superoxide anion production (Pritchard
et al., 1995; Wilson et al., 2001). The contribution of
increased nitrotyrosine formation to the development of
atherosclerosis and thus to CAD has been demonstrated in
patients with hypercholesterolaemia in combination with
CAD (Shishehbor et al., 2003). Experimental hypercholes-
terolaemia is associated with increased myocardial oxidative
stress and inflammation, attenuation of cell survival path-
ways and the induction of apoptosis (Wang et al., 2002;
Osipov et al., 2009).
Additionally, it should be noted that the extent of
myocardial injury after ischaemia/reperfusion is deter-
mined not only by the tolerance of cardiomyocytes to
ischaemia/reperfusion injury but also by the coronary collat-
eral blood flow and rate-pressure product at the time of myo-
cardial ischaemia (Reimer et al., 1985). LDL up-regulates the
renin-angiotensin system (RAS), leading to increased genera-
tion of angiotensin II, which in turn, binds to the type 1
angiotensin II receptor (AT1 receptor) and activates a signal-
ling cascade that results in the enhanced accumulation of
the cholesteryl ester (Rafatian et al., 2013). In particular, hy-
percholesterolaemia seems to promote the up-regulation of
AT1 receptor genes followed by the structural overexpression
of vascular AT1 receptors for angiotensin II (Borghi et al.,
2016). Studies in rabbits showed that hypercholesterolaemia
increased cardiac diastolic pressure after 1 month of choles-
terol treatment, and this was correlated with increased levels
of superoxide in the aortas, and to a higher expression of
NADPH subunits, associated with altered vasorelaxation
(Collin et al., 2007). Clinical studies have also suggested a role
of some lipoprotein subfractions as risk factors for the devel-
opment of hypertension (see for a recent review: Borghi
et al., 2016). The development of vascular damage in patients
with hypercholesterolaemia could also involve the activation
of the RAS, and although the mechanisms of interaction be-
tween hypercholesterolaemia and hypertension have not
been completely elucidated, there is growing evidence that
the involvement of RAS can be considered as a common link
between hypertension and hypercholesterolaemia.
Effect of hypercholesterolaemia on
cardioprotection induced by ischaemic
preconditioning
Initially, hypercholesterolaemia was shown to alter re-
sponses to ischaemic preconditioning (PC); pacing-induced
PC was blocked in hypercholesterolaemic rabbits and rats
(Szilvassy et al., 1995). This loss of pacing-induced PC was
further noted in another experimental model, in rats
administered a cholesterol-enriched diet for 24 weeks
(Ferdinandy et al., 1997). Furthermore, isolated papillary
muscle from rats fed a high-fat diet was more susceptible
to the effects of ischaemia and less protected by the effects
of PC compared with controls (Kocić et al., 1999). Although
studies performed in mice and rats showed consistent re-
sults, divergent results have been observed in anaesthetised
rabbits. The infarct size-limiting effect of one cycle PC
(5 min occlusion and 10 min reperfusion) was shown to
be blunted in the hypercholesterolaemic (16 weeks) rabbit
heart subjected to ischaemia/reperfusion (Ueda et al.,
1999), whereas hypercholesterolaemia (8 weeks) did not at-
tenuate the reduction in myocardial infarction in rabbits
subjected to one cycle of PC, comprising 5 min of regional
ischaemia plus 10 min reperfusion (Kremastinos et al.,
2000). The difference between the above protocols was the
duration of cholesterol feeding, that is, 16 versus 8 weeks.
Similar results were obtained in a later study, using two cy-
cles of 5 min ischaemia followed by 10 min reperfusion be-
fore sustained ischaemia as a PC stimulus, corroborating the
finding that PC limits the infarct size in hypercholesterolae-
mic animals (Iliodromitis et al., 2006). Consistent with the
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latter results, Jung et al. showed that hypercholesterolaemia
did not affect the beneficial influence of PC on infarct mass
(Jung et al., 2000).
In patients with hypercholesterolaemia, an early cardio-
myopathy characterized by systolic and diastolic dysfunction
has been observed, producing a substratum for an ‘impaired
preconditioning’ (Talini et al., 2008). In this respect, two clin-
ical studies investigated the effect of conditioning interven-
tions in the context of hypercholesterolaemia. Both studies
examined the effects of repeated balloon inflations at the
time of angioplasty in patients with CAD and demonstrated
that hypercholesterolaemia attenuated the anti-ischaemic
effect of preconditioning during coronary angioplasty
(Kyriakides et al., 2002; Ungi et al., 2005). Moreover,
hypercholesterolaemia accelerated the development of
intracoronary ST-segment elevation in humans (Ungi et al.,
2005).
In summary, divergent results exist in the literature
concerning cardioprotection by PC in the presence of hyper-
cholesterolaemia. While shorter durations of hypercholester-
olaemia may not affect the cardioprotective signalling of PC,
longer durations may disrupt this cardioprotective effect.
This was observed in animal studies and has been confirmed
in clinical trials.
Mechanisms of the interaction between
ischaemic preconditioning and
hypercholesterolaemia
Several potential mechanisms have been proposed to explain
the lack of a PC effect in hypercholesterolaemia. Since hyper-
cholesterolaemia is linked to oxidative/nitrosative stress in
the vasculature and in the myocardium (Szilvassy et al.,
2001; Giricz et al., 2006) and to a decreasedNObioavailability,
many studies have focused on the role of NO as a potential
mechanism of PC’s lost effect. A low concentration of NO is
associated with a high concentration of asymmetric
dimethylarginine (ADMA), and it has been shown that during
hypercholesterolaemia the level of ADMA is elevated and the
cardioprotective effects of PC are eliminated in rats (Landim
et al., 2013). The beneficial effects of late PC were shown to
be abolished in an in vivo rabbit model of hypercholesterolae-
mia, due to an impaired up-regulation of BH4, which is essen-
tial for inducible NOS (iNOS) (Tang et al., 2005).
With regard to the involvement of apoptosis signalling in
the effects of PC, it has been shown that hypercholesterolae-
mia prevents the effects of sevoflurane-induced PC by alter-
ing the upstream signalling of glycogen synthase kinase 3 β
(GSK3β) indicating that acute GSK inhibition may provide a
novel therapeutic strategy to protect hypercholesterolaemic
hearts against ischaemia/reperfusion injury (Ma et al.,
2013). In isolated hearts from cholesterol-fed rats, the protec-
tive effect of PC mediated by moderate inhibition of MMP2
was blocked, whereas a reduction in infarct size could be pro-
duced using an MMP inhibitor in non-preconditioned hearts
(Giricz et al., 2006; Bencsik et al., 2014). Hypercholesterolae-
mia also causes an alteration in one of the main signal trans-
duction elements of the conditioning mechanism, connexin,
producing a redistribution of the intracellular localization of
connexin 43 in the cardiomyocytes, and this might be a
potential explanation for the loss of the myocardial
infarction-limiting effect of PC in the presence of hypercho-
lesterolaemia (Görbe et al., 2011).
The effects of PC in ischaemia/reperfusion injury during
hypercholesterolaemia and the proposed mechanisms are
summarized in Table 1.
Effect of hypercholesterolaemia on
cardioprotection induced by ischaemic
postconditioning
PostC triggered by two different algorithms (six cycles of 10 s
ischaemia separated by 10 s reperfusion, and four cycles of
30 s ischaemia separated by 30 s reperfusion immediately af-
ter the end of the index ischaemia) has been found to be inef-
fective at limiting the infarct size in anaesthetised rabbits
with hypercholesterolaemia and atherosclerosis (Iliodromitis
et al., 2006). This initial observation was further confirmed in
mini swines (Zhao et al., 2007) and in hypercholesterolaemic
rats (Kupai et al., 2009). In contrast to the above findings, in
rabbit isolated crystalloid-perfused hearts, PostC reduced
the infarct size in hypercholesterolaemic animals (Donato
et al., 2007) and the same result was observed in hypercholes-
terolaemic rats (Zhao et al., 2009). These results may show
that some components of the hypercholesterolaemic blood
contributes to the attenuation of the effectiveness of PostC
in hypercholesterolaemia.
In summary, although studies are not consistent, most of
the robust studies showed that cardioprotection by PostC is
abolished in the presence of hypercholesterolaemia, indicat-
ing that hypercholesterolaemia interferes with the molecular
signalling of PostC.
Mechanisms of the interaction between
ischaemic postconditioning and
hypercholesterolaemia
NO pathway and nitro-oxidative stress. The myocardial NO-
cGMP pathway seems to be impaired in
hypercholesterolaemia. In hypercholesterolaemic rats,
phosphorylation of eNOS and Akt was decreased compared
with controls, which may result in a decrease in NO
production, and the loss of effect of cardioprotective
interventions (Penumathsa et al., 2007). Similar results and
a decreased phosphorylation of eNOS were found in
hypercholesterolaemic rabbits (Andreadou et al., 2012).
Similar to the findings mentioned above for PC, a low
concentration of NO is associated with a high concentration
of ADMA, hypercholesterolaemia elevated ADMA and
eliminated the cardioprotective effects of PostC in rats. It
has also been shown that although hypercholesterolaemia
did not modulate the basal expression of PKG, its oxidized
dimeric form was more abundant in hearts of
hypercholesterolaemic animals possibly due to increased
oxidative stress (Giricz et al., 2009). It is interesting to note
that PostC increased cardiac 3-nitrotyrosine concentrations
in the normally fed rats but not in the cholesterol-fed
group, when measured at the fifth minute of reperfusion,
indicating that an early increase in peroxynitrite after PostC
plays a role in cardioprotection (Kupai et al., 2009). In
contrast, in rabbit myocardium, PostC reduced nitrotyrosine
concentrations in the normal fed group but not in the
cholesterol-fed group at the 10th minute of reperfusion,
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indicating that inhibition of nitrosative stress plays a role in
cardioprotection (Andreadou et al., 2012). These
controversial results concerning the mechanisms of
cardioprotection vary according to quality, composition and
time of administration of the high-cholesterol diet, as well
as the species used in each experiment.
Apoptosis and reperfusion injury salvage kinase
signalling. Other factors that have been proposed to
account for the larger myocardial infarction observed in
hypercholesterolaemia include heat shock protein-70,
which is down-regulated in hypercholesterolaemia (Csont
et al., 2002) and caspase-3, the activation of which is
increased in hypercholesterolaemic ischaemic rabbit
myocardium (Wang et al., 2002). Hypercholesterolaemia
prevents the sevoflurane-induced cardioprotection against
ischaemia/reperfusion injury by alterating the upstream
signalling of GSK3β (Xu et al., 2013). In another study that
investigated the cardioprotection of PostC in
hypercholesterolaemic rat isolated hearts, it was observed
that infarct size and cardiomyocyte apoptosis were
completely abolished by hypercholesterolaemia due to the
impairment of phosphorylation of GSK3β and attenuation
of mitochondrial permeability transition pore (mPTP)
opening (Wu et al., 2014a).
The roles of reperfusion injury salvage kinases (RISK)
and apoptosis-related pathways in the attenuation of
cardioprotection of PostC were recently investigated in rat
isolated hearts. The results showed that PostC significantly
decreased the infarct size and apoptosis, and improved the
functional recovery of ischaemic myocardium, but these
beneficial effects were reversed by a high-cholesterol diet.
Table 1
Effect of hypercholesterolaemia (HC) on cardioprotection induced by ischaemic and pharmacological PC
Experimental model Effect on PC Proposed mechanism(s) Reference
Isolated rat hearts
subjected to PC
Elimination of infarct size
reduction by PC
HC abolished PC-induced inhibition of
myocardial MMP2 activation and release
Giricz et al., 2009
Isolated rat hearts
subjected to PC
Elimination of infarct size
reduction by PC
Loss of cardioprotection by PC in HC is
associated with a redistribution of both
sarcolemmal and mitochondrial
connexin 43
Görbe et al., 2011
Rats exposed to
pacing-induced PC
Elimination of pacing-induced
cardioprotection by PC
HC induced deterioration of cardiac
NO metabolism
Ferdinandy et al., 1997
Rats subjected to
three cycles of PC
Elimination of infarct size
reduction by PC
HC elevated ADMA and eliminated the
cardioprotective effects of PC
Landim et al., 2013
Rabbits exposed to
pacing-induced PC
Elimination of pacing-induced
cardioprotection by PC
HC impaired cardiac NO synthesis Szilvassy et al., 1995;
Ferdinandy et al., 1998a,b
Rabbits subjected
to one cycle PC
Elimination of the infarct
size-limiting effect of PC
HC prevented ecto-50-nucleotidase
activation by PC
Ueda et al., 1999
Rabbits subjected
to one cycle of PC
Myocardial infarction reduction
by PC was not attenuated by HC
Observational study Kremastinos et al., 2000
Rabbits subjected
to two cycles of PC
Myocardial infarction reduction
by PC was not attenuated by HC
Observational study Iliodromitis et al., 2006
Rabbits subjected
to one cycle of PC
Myocardial infarction reduction
by PC was not attenuated by HC
Reduced calcium-ionophore stimulated
endothelial NO-release were found in
isolated aortic rings of hypercholesterolemic
animals suggesting that NO produced by
the endothelium is not a prime factor in
the cardioprotective mechanism of PC
Jung et al., 2000
Rabbits subjected
to late PC
Elimination of infarct size
reduction by late PC
Impaired up-regulation of BH4, which is
essential for inducible nitric oxide
(NO) synthase
Tang et al., 2005
Sevoflurane-induced
PC in rats
Elimination of sevoflurane-induced
cardioprotection
HC alterated the upstream signalling of
GSK3β
Ma et al., 2013
Sevoflurane-induced
PC in rats
Elimination of sevoflurane-induced
cardioprotection
Interference with the iNOS/mitochondrial
ATP-dependent K+ channel pathway
Zhang et al., 2012
Fasudil induced
pharmacological
PC in rats
Low-dose fasudil-induced PC is
abolished by HC, but only high-dose
restored the cardioprotection
Fasudil up-regulated the PI3K/Akt/eNOS
pathway and induced the opening of
the mito-KATP channel
Wu et al., 2014b
NO donors induced
late PC in rabbits
Hypercholesterolaemia blunted
NO donor (diethylenetriamine/NO)
-induced late PC
Disruption of biochemical pathways
distal to the generation of NO
Tang et al., 2004
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Moreover, hypercholesterolaemia inhibited the phosphory-
lation of Akt and ERK1/2, which were activated by PostC in
normal hearts, and induced excessive apoptosis by down-
regulating B-cell lymphoma 2 (Bcl-2) and up-regulating
bcl-2-like protein 4, cytochrome c, caspase 9 and caspase
3. These results indicate that the hypercholesterolaemia-
induced loss of cardioprotection conferred by PostC is
associated with inactivation of the RISK signalling pathway
and dysregulation of the downstream apoptosis-related
pathway (Wu et al., 2015a).
Furthermore, it has been shown that PostC reduces themyo-
cardial injury in hypercholesterolaemic rats probably by the up-
regulation of hypoxia-inducible factor 1-α (HIF-1α), which may
be involved in the PostC-mediated cardioprotective mecha-
nisms (Zhao et al., 2009). This was further confirmed by an-
other study, which showed that when dimethyloxalylglycine
was given before PostC to up-regulate HIF-1α protein level,
the degree of ischaemia/reperfusion injury was attenuated in
hypercholesterolaemic rats suggesting that an up-regulation
of HIF-1α may be one of the cardioprotective mechanisms of
PostC against ischaemia/reperfusion injury in hypercholester-
olaemia (Li et al., 2014).
ATP-sensitive potassium channels. Divergent results exist on the
role of both mitochondrial and sarcolemal ATP-sensitive
potassium channels (KATP channels also known as Kir6.2
channels) in hypercholesterolaemia. In rabbit isolated hearts,
PostC reduced the infarct size in hypercholesterolaemic
animals through the activation of adenosine A1 receptors and
KATP channels (Donato et al., 2007). In contrast, the infarct-size
reducing effect of either the nonselective KATP activator
cromakalim or the selective mitoKATP activator diazoxide was
lost in hearts of hyperlcholesterolaemic rats, showing that
hypercholesterolaemia may influence KATP channel function
in the heart. Although the mechanism by which
hypercholesterolaemia inhibits the cardioprotective effect of
KATP modulators is not known, altered energy metabolism as
well as increased oxidative stress, but not changes in the
expression levels of functional KATP protein expression in the
heart, due to the cholesterol diet have been shown to be
involved (Csonka et al., 2014).
Mitochonrial permeability transition pore. The blocking of the
mPTP with cyclosporine A (CsA) was investigated in order to
determine whether it can restore the cardioprotection of
PostC in hypercholesterolaemic rat hearts. It was concluded
that the effect of PostC blocked by hypercholesterolaemia
may be due to the excessive opening of the mPTP, and thus,
inhibiting the mPTP with CsA is able to reverse this loss of
cardioprotection observed during hypercholesterolaemia
(Wu et al., 2015c).
The effects of PostC in ischaemia/reperfusion injury in
the presence of hypercholesterolaemia and the proposed
mechanisms are summarized in Table 2.
Effect of hypercholesterolaemia on
cardioprotection induced by remote
conditioning
To the best of our knowledge, there is only one very recent
study investigating whether remote preconditioning (RIPC)-
induced cardioprotection is intact in hypercholesterolaemia.
In this study, RIPC failed to reduce myocardial necrosis and
apoptosis in hypercholesterolaemic myocardium in rats.
Importantly, the authors found that inhibition of GSK3β
reduced myocardial infarct size in hypercholesterolaemic
hearts, but no additional cardioprotective effect was achieved
when combined with RIPC, suggesting that acute GSK3β
inhibition may provide a novel therapeutic strategy for
hypercholesterolaemic patients during AMI, whereas RIPC is
less effective due to signalling events that adversely affect
GSK3β (Ma et al., 2016).
Effect of hypercholesterolaemia on
drug-induced cardioprotection
Although a number of drugs have been shown to be effec-
tive in preventing myocardial ischaemic-reperfusion injury,
few are capable of preserving cardioprotection in the
presence of hypercholesterolaemia (Balakumar and Babbar
2012). In addition to studies that refer to the application
of PC as a manoeuvre, some studies have also examined
the role of pharmacologically- induced PC during
hypercholesterolaemia. It is well established that volatile
anaesthetic-induced PC confers myocardial protection
against ischaemia–reperfusion; however, hypercholesterol-
aemia abolished the sevoflurane-induced cardioprotection
in rats (Ma et al., 2013). Although sevoflurane-induced PC
exerts delayed cardioprotection in normocholesterolaemic
rats, this beneficial effect was blocked by hypercholesterol-
aemia probably by an effect on the iNOS/mitochondrial
ATP-dependent K+ channel pathway (Zhang et al., 2012).
Fasudil, a Rho-kinase inhibitor, has been shown to induce
pharmacological PC in rats. However, low-dose fasudil-
induced PC is abolished by hypercholesterolaemia and only
a high-dose restored the cardioprotection (Wu et al., 2014b).
Conversely, fasudil was effective at restoring the
cardioprotection of PostC in the hypercholesterolaemic rat
heart. This effect was mediated by the activation of the
PI3K/Akt/eNOS signalling pathway and an increase in the
myocardial NO content (Wu et al., 2014c).
Another example of the effect of hypercholesterolaemia
on drug-induced PC are NO donors, which have been shown
to confer late PC againstmyocardial ischaemia/reperfusion in
healthy rabbits. Hypercholesterolaemia blunted the late PC
mediated by the NO donor (diethylenetriamine), indicating
that the inhibitory effects of hypercholesterolaemia on NO
donor-induced late PC in conscious rabbits are caused by
the disruption of biochemical pathways distal to the genera-
tion of NO that triggers these adaptations (Tang et al., 2004).
In hyperlcholesterolaemic rat hearts, the NO donor S-
nitroso-N-acetyl-D,L-penicillamine (SNAP), brain natriuretic
peptide (BNP-32) and exogenous cGMP failed to induce
cardioprotection, suggesting that the defect in cytoprotective
signalling in the hypercholesterolaemic myocardiummay re-
side downstream of cGMP elevation probably at the level of
PKG (Giricz et al., 2009).
The loss of pacing-induced PC could be recaptured by the
key polyprenyl product farnesol in hypercholesterolaemia;
however, farnesol-treatment did not influence cardiac NO
content in the cholesterol-fed rats or in the normal fed rats
(Ferdinandy et al., 1998b). Furthermore, the infarct-size
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limiting effect of cromakalim (a nonselective KATP channel
activator) or diazoxide (a selective mitoKATP channel activa-
tor) was lost in hypercholesterolaemic rats (Csonka et al.,
2014).
It is well established that hypercholesterolaemia is accom-
panied by a decrease in cardiac NO content and increased
nitro-oxidative stress; however, the role of NO donors in
ischaemia/reperfusion injury with or without hypercholes-
terolaemia is not well established. Although NO treatment
prior to or during the early reperfusion period can limit in-
farct size in preclinical studies, the excessive production of
NO at the beginning of reperfusion reacts with ROS and
forms peroxynitrite (see for reviews: Andreadou et al., 2015;
Bice et al., 2016). The three clinical studies with NO donors
that have been performed so far have revealed no evidence
of infarct size reduction in patients treated with NO donors
immediately prior to reperfusion. Additionally, high concen-
trations of NO can promote cellular injury, a situation that is
possible in patients being treated with several co-medications
including nitrates. Hence, cardioprotection by NO donors
should be demonstrated in experimental models with co-
morbidities and relevant co-medications prior to clinical
translation (Ferdinandy et al., 2014; Andreadou et al., 2015;
Bell et al., 2016; Bice et al., 2016).
Effect of antihyperlipidaemic drugs on the
ischaemic heart and cardioprotection
Statins. Elevated cholesterol levels can be decreased by diet,
exercise and appropriate medical therapy. Among the various
hypolipidaemic agents, statins confer the main benefit in
treated patients by substantially decreasing cardiovascular
morbidity and mortality. Apart from the significant decrease
in cholesterol levels, statins also have pleiotropic effects,
which, albeit exaggerated, may provide additional benefits.
In fact, experimental and clinical studies have shown that
statins are involved in a reduction in reperfusion injury and
inflammatory reactions and in the improvement in the
Table 2
Effect of HC on cardioprotection induced by PostC
Experimental model Effect of PostC Proposed mechanism(s) Reference
Isolated rat hearts
subjected to PostC
Elimination of infarct size reduction
and cardiomyocyte apoptosis
Impairment of phosphorylation of
GSK3β and attenuation of mPTP
opening
Wu et al., 2014a
Isolated rat hearts
subjected to PostC
Elimination of infarct size reduction
and apoptosis
Inactivation of RISK signal pathway
and dysregulation of downstream
apoptosis-related pathway
Wu et al., 2015a
Rats subjected to PostC Elimination of infarct size limiting
effects of PostC
ΗC blocked the cardioprotective
effect of PostC at least in part via
deterioration of the PostC-induced
early increase in peroxynitrite
formation
Kupai et al., 2009
Rats subjected to PostC Myocardial infarction reduction
was not attenuated by
hypercholesterolemia
HIF-1α up-regulation Zhao et al. 2009;
Li et al., 2014
Rats subjected to PostC Elimination of PostC cardioprotection Elevation of ADMA Landim et al., 2013
Isolated rabbit hearts
subjected to PostC
Myocardial infarction reduction
was not attenuated by
hypercholesterolaemia
Activation of A1 receptors and
KATP channels
Donato et al., 2007
Rabbits subjected to PostC
triggered by two different
algorithms (six cycles of
10 s ischaemia separated
by 10 s reperfusion and
four cycles of 30 s ischaemia
separated by 30 s reperfusion
immediately after the end
of the index ischaemia)
Elimination of infarct size
limiting effects of PostC
Observational study Iliodromitis et al., 2006
Rabbits subjected to PostC Elimination of PostC cardioprotection Increased oxidative and
nitrosative stress
Iliodromitis et al., 2010
Rabbits subjected to PostC Elimination of PostC cardioprotection Decreased phosphorylation
of eNOS
Andreadou et al., 2012
Mini swines subjected
to PostC
Elimination of the reduction of
the no-reflow and necrosis areas
Ηypercholesterolaemia increased
the area of no-reflow
Zhao et al., 2007
Sevoflurane-induced
PostC in rats
Elimination of sevoflurane-induced
cardioprotection
Alteration of upstream signalling
of GSK3β
Xu et al., 2013
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microcirculation. Statins are implicated in the generation of
intracellular mediators, which may prevent mPTP opening
and therefore preserve mitochondrial integrity and the
survival of cells (Ludman et al., 2009; Antoniades and
Channon, 2014; Mihos et al., 2014). However, a growing body
of evidence suggests that the cardioprotective potential of
statins, associated with their pleiotropic and anti-
inflammatory effects, is mediated by the up-regulation and
activation of PPARα (Balakumar and Mahadevan 2012;
Ravingerova et al., 2015). Many experimental studies have
shown that statins reduce infarct size in hypercholesterolaemic
animals (Penumathsa et al., 2007); therefore, in the present
review, we will focus on the role of statin administration on
the cardioprotective mechanisms (PC and PostC).
There are biological differences between lipophilic and
hydrophilic statins. Lovastatin prevents the cardioprotective
effect of PC when applied acutely but not when given chron-
ically. The cardioprotective effect of PostC was attenuated
when chronic lovastatin treatment was applied, whereas
acute lovastatin treatment had no effect (Kocsis et al., 2008).
Furthermore, acute and chronic lovastatin treatment show
differential effects on the p42/p44MAPK pathway; only acute
lovastatin treatment significantly increased p42/p44 MAPK
phosphorylation. These effects of lovastatin might play a role
in its differential action on cardioprotective mechanisms
(Kocsis et al., 2008) The most hydrophilic statin, pravastatin,
at a dose in which serum cholesterol was not normalized, re-
stored the infarct size-limiting effect of PC in hypercholester-
olaemic rabbits, although it did not reduce the infarct size
when it was administered without PC (Ueda et al., 1999).
The activation of ecto-50-nucleotidase was suggested as a pos-
sible mechanism for the hypercholesterolaemia-induced re-
tardation and pravastatin-mediated restoration of the
cardioprotective effect of PC (Ueda et al., 1999).
The loss of PostC benefits could be reversed by a 3 week
simvastatin treatment, which limits the infarct size both in
normo- and in hypercholesterolaemic rabbits subjected to
ischaemia–reperfusion irrespective of the presence of PostC,
while PostC is effective only in normocholesterolaemic ani-
mals. One should deduce that simvastatin also reduced total
cholesterol and LDL plasma levels and attenuated the oxida-
tive and nitrosative stress in the ischaemic myocardium
(Iliodromitis et al., 2010). However, the infarct size limitation
by simvastatin was lost in hyperlcholesterolaemic animals,
when simvastatin was administered for a short time period
and did not possess hypolipidaemic activities (Andreadou
et al., 2012). In contrast, short-term administration of prava-
statin at the same dose as simvastatin reduced infarction in
cholesterol-fed rabbits independently of any lipid lowering
effect, potentially through eNOS activation and the attenua-
tion of nitro-oxidative stress. The open lactone ring chemical
structure of pravastatin prevents its plasma protein binding
by 100 times compared to simvastatin. This may partly be re-
lated to the high 45% unbound fraction of pravastatin so-
dium in plasma, which may interact actively with the
endothelium and activate the eNOS/Akt signalling cascade
(Andreadou et al., 2012).
Fibrates. Fibrates, such as fenofibrate, bezafibrate,
ciprofibrate and clofibrate, are PPARα agonists widely used
clinically for treating dyslipidaemias (Staels et al., 1998).
Fibrates have been suggested to improve the prognosis for
ischaemic heart disease due to other non-lipid effects that
are directly associated with the activation of PPARα,
resulting in numerous changes in gene transcription
including the genes regulating lipid metabolism
(Schoonjans et al., 1996; Ravingerova et al., 2015). Although
accumulating data have demonstrated the role of PPAR
activation in mediating cardioprotection in the setting of
ischaemia/reperfusion in various experimental animal
models (Ravingerová et al., 2012; Barlaka et al. 2013; Barlaka
et al., 2016), evidence for the effectiveness of fibrates in
restoring the lost cardioprotection of PC or PostC in
hyperlcholesterolaemic animals is scarce. Treatment
with fenofibrate markedly restored the cardioprotective
and infarct size limiting properties of PC in
hypercholesterolaemic rat hearts, whereas it did not affect
the cardioprotection by PC in normal rat hearts (Singh et al.,
2014). Although this effect has not yet been corroborated in
subsequent studies and the underlying mechanism is
unclear, it is pausible that activation of PPARα, which is
markedly down-regulated in hypercholesterolaemic rat heart
after ischaemia/reperfusion, and subsequent activation of
the PI3K/Akt/eNOS pathway may restore the lost
cardioprotection in hypercholesterolaemic hearts. In this
context, PPARα up-regulation confers preconditioning-like
protection against ischaemia/reperfusion via metabolic
effects whereas PI3K/Akt activation may also be involved in
the downstreammechanisms (Ravingerová et al., 2012; 2015).
Niacin. Another hypolipidaemic drug with pleiotropic
properties is nicotinic acid (niacin), which inhibits platelet
activation, and reduces the expression of pro-inflammatory
vascular cell adhesion molecule-1 (VCAM-1; Stach et al.,
2012) and oxidative stress (Gouni-Berthold and Berthold
2013), in addition to modulating the lipid profile. To the
best of our knowledge, there are no data associating niacin
with the cardioprotective effect of PC or PostC or its loss in
the hypercholesterolaemic heart.
PCSK9 inhibitors. Inhibition of the proprotein convertase
subtilisin-kexin type 9 (PCSK9) leads to an increased density
of cell surface LDL receptors and therefore a reduction in
serum LDL. Several monoclonal antibodies targeting PCSK9
have been developed recently and used as anti-
hypercholesterolaemic drugs (Cohen et al., 2006).
Nevertheless, there are no data in the literature regarding
the possible influence of PCSK9 inhibition on the
cardioprotective effect of conditioning. Therefore, it would
be of great importance to evaluate if these new anti-
hypercholesterolaemic drugs can affect the efficacy or safety
of cardioprotection elicited by conditioning strategies.
Conclusions and perspectives
Hypercholesterolaemia changes cardiac transcriptomics, cellular
signalling andmetabolism leading tomild diastolic dysfunction
and endothelial dysfunction. Moreover, hypercholesterolaemia
worsens the outcome of ischaemia/reperfusion injury and
attenuates the cardioprotective effect of preconditioning,
PostC, remote conditioning, as well as pharmacological
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cardioprotection by interfereing with cardioprotective signal-
ling pathways (Figure 1). Our review highlights the relative lack
of experimental and especially clinical data looking at
cardioprotection in treated or untreated hypercholesterolaemic
animal models and patients, as well as the lack of knowledge
on the effect of antihyperlipidaemic drugs on the ischaemic
heart and cardioprotective signalling. Therefore, the establish-
ment ofmore clinically relevant preclinicalmodels of hypercho-
lesterolaemia, together with the identification of novel targets
are needed for the development of new cardioprotective drugs
Figure 1
Effect of hypercholesterolaemia on major known cardioprotective cellular mechanisms induced by conditioning interventions: Hypercholesterol-
aemia inhibits the phosphorylation of Akt and impairs the myocardial NO-cGMP pathway leading to inhibition of mitochondrial KATP channel
opening. Additionally, impairment of the inhibition of GSK3β may cause excessive opening of the mPTP leading to mitochondrial swelling and
cell death. Hypercholesterolaemia also inhibits the phosphorylation of extracellular-ERK1/2 and induces down-regulation of HIF-1α, which is
one of the cardioprotective mechanisms of PostC. Hypercholesterolaemia produces excessive apoptosis by down-regulating Bcl-2 and up-regu-
lating Bcl-2-like protein 4 (Bax), cytochrome c, caspase 9 and caspase 3. Hypercholesterolaemia inhibits mitochondrial translocation of connexin
43 (Cx43). Hypercholesterolaemia produces an increased generation of superoxide anion and a decreased bioavailability of NO through, for ex-
ample, eNOS and iNOS uncoupling by a reduction in the NOS cofactor BH4. Therefore, during hypercholesterolaemia, an increased formation of
peroxynitrite, a toxic reaction product of superoxide and NO, is observed that further depletes bioavailability of NO in the heart. Moreover, the
inhibition of oxidative activation of MMP2 by conditioning is blocked in hypercholesterolaemia due to peroxynitrite-induced activation of MMP2.
Green boxes and dashed arrows denote major cardioprotective pathways that are affected by hypercholesterolaemia. Orange boxes and arrows
indicate major influence of hypercholesterolaemia on cardioprotective cellular pathways.
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that will be able to reverse the increased susceptibility of hyper-
cholesterolaemic hearts to ischaemia/reperfusion injury and to
provide cardioprotection.
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